Trial · NCT05907499
Decitabine for Poor Graft Function Post Allo-HSCT
NCT05907499, Phase 3, Completed, The First Affiliated Hospital of Soochow University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Decitabine for Poor Graft Function Post Allo-HSCT. Trials, record NCT05907499. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05907499
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Decitabine for Poor Graft Function Post Allo-HSCT
- NCT number
- NCT05907499
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 76 participants, actual
- Lead sponsor
- The First Affiliated Hospital of Soochow University
- Conditions
- Poor Graft Function
- Interventions
- Decitabine, Granulocyte Colony-Stimulating Factor, Thrombopoietin Receptor Agonist, Recombinant human erythropoietin
- First posted
- 2023-06-18
- Last updated
- 2026-10-23
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants Achieving Treatment Response (Hematological Response + Hematological Improvement) | day +28 | Hematological response (HR) was defined as recovery in all cell lineages (neutrophils ≥ 1.5 x 109/L, platelets ≥ 30 x 109/L and hemoglobin ≥ 85 g/L) without the need for transfusion or growth factor support for consecutive 7 days. Hematological improvement (HI) was defined as recovery of at least 1 lineage. No response (NR) refers to those who failed to reach HR or HI. |
| Primary | Overall Survival Rate | 1 year | Overall survival was calculated from time of random assignment to death from any cause |
| Secondary | Number of Participants With Bone Marrow Recovery | day +28 | Bone marrow recovery was assessed using quantitative morphometric analysis to determine marrow cellularity, the myeloid-to-erythroid ratio, and megakaryocyte counts. |
| Secondary | Number of Participants With Relapse | 3-month | Relapse was defined according to the European LeukemiaNet (ELN) guidelines |
| Secondary | Event Free Survival Rate | 1 year | EFS referred to time from random assignment to disease progression /relapse, severe bleeding events, severe infections or death from any cause. |
| Secondary | Number of Participants With GVHD | 3-month | Diagnosis and grading of GVHD was performed according to NCCN Clinical Practice Guidelines, 2020 |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers12
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05907499
GET https://conductscience.org/api/trials/v1/NCT05907499/registered